Calcium (Ca²⁺) is a critical second messenger that regulates numerous cellular processes including neurotransmitter release, synaptic plasticity, gene transcription, and cell survival. Maintaining calcium homeostasis is essential for neuronal function, and dysregulation of calcium signaling is a hallmark feature of both Alzheimer's disease (AD) and Parkinson's disease (PD) [1]. [@lee2019]
flowchart TD
A["Calcium Dysregulation<br/>(Pathological Trigger)[^1]"]:::red --> B["ER Ca²⁺ Depletion"]
A --> C["Elevated Cytosolic Ca²⁺"]
A --> D["Store-Operated<br/>Ca²⁺ Entry (SOCE)"]
B --> E["Unfolded Protein Response<br/>ER Stress[^2]"]
C --> F["Calpain Activation<br/>(Ca²⁺-dependent Proteases)[^3]"]
D --> G["Neuroinflammation[^4]"]
E --> H["Mitochondrial Ca²⁺ Overload"]
F --> H
G --> H
H --> I["Mitochondrial Dysfunction"]
I --> J["ATP Depletion"]
I --> K["ROS Production"]
I --> L["Cytochrome c Release"]
J --> M["Apoptosis"]
K --> M
L --> M
M --> N["Neuronal Death"]:::red
click A "/mechanisms/calcium-dysregulation" "Calcium Dysregulation"
click B "/mechanisms/er-stress-pathway" "ER Stress"
click I "/mechanisms/mitochondrial-dysfunction" "Mitochondrial Dysfunction"
click G "/mechanisms/ad-neuroinflammation-microglia-pathway" "Neuroinflammation"
click N "/diseases/alzheimers-disease" "Alzheimer's Disease"
style A fill:#e1f5fe,stroke:#333
style B fill:#fff3e0,stroke:#333
style C fill:#e1f5fe,stroke:#333
style D fill:#e1f5fe,stroke:#333
style E fill:#fff3e0,stroke:#333
style F fill:#fff3e0,stroke:#333
style G fill:#fff3e0,stroke:#333
style H fill:#fff3e0,stroke:#333
style I fill:#fff3e0,stroke:#333
style J fill:#c8e6c9,stroke:#333
style K fill:#ffcdd2,stroke:#333
style L fill:#ffcdd2,stroke:#333
style M fill:#fff9c4,stroke:#333
style N fill:#ffcdd2,stroke:#333
The endoplasmic reticulum (ER) serves as the major intracellular calcium store. In neurodegenerative conditions, ER calcium depletion occurs through multiple mechanisms: [@wang2020]
- Amyloid-β oligomers directly interact with ER calcium channels, promoting calcium release [2]
- α-Synuclein aggregation disrupts ER-mitochondria calcium transfer via the MAM (mitochondria-associated ER membrane) [3]
- Genetic mutations in proteins like presenilin can cause ER calcium dysregulation
Elevated cytosolic calcium activates calcium-dependent proteases called calpains: [@liu2018]
- Calpain activation leads to cleavage of structural proteins, including spectrin
- Activated calpains cleave regulatory proteins including phosphatases and kinases
- Calpain-mediated proteolysis contributes to synaptic dysfunction
Mitochondria act as calcium buffers, but excessive calcium uptake is detrimental: [@zundorf2011]
- Mitochondrial calcium overload opens the mitochondrial permeability transition pore (mPTP)
- This leads to loss of mitochondrial membrane potential
- ATP production is impaired
- Pro-apoptotic factors including cytochrome c are released
The intrinsic apoptotic pathway is activated: [@celsi2009]
- Cytochrome c release triggers caspase-9 activation
- Caspase cascade leads to neuronal apoptosis
- This pathway contributes to progressive neuronal loss in both AD and PD
- Amyloid-β affects NMDA receptor trafficking, enhancing calcium influx
- Presenilin mutations (FAD mutations) cause ER calcium hyperexcitability
- Tau pathology correlates with calcium dysregulation severity
- α-Synuclein aggregates disrupt ER-mitochondria contact sites
- LRRK2 mutations affect calcium handling
- Mitochondrial complex I deficiency exacerbates calcium dysregulation
| Target | Strategy | Status | [@palop2010]
|--------|----------|--------| [@sepulvedafalla2014]
| VGCC blockers | L-type channel inhibition | Preclinical | [@hirrlinger2009]
| Calpain inhibitors | Protease activity modulation | Early trials | [@weick2015]
| ER stress modulators | UPR pathway modulation | Preclinical | [@cao2018]
| mPTP inhibitors | Pore opening prevention | Preclinical | [@calcium2010]
- Store-operated calcium entry (SOCE) modulators
- Mitochondrial calcium uniporter (MCU) targeting
- Calmodulin signaling pathway modulators
Calcium dysregulation represents a convergent pathway in neurodegeneration, linking multiple pathological triggers to neuronal death. Understanding the complex interplay between ER calcium depletion, mitochondrial calcium overload, and apoptotic signaling provides opportunities for therapeutic intervention across multiple neurodegenerative diseases. [@excitotoxicity2011]
--- [@calcium2012]
Additional evidence sources: [@gene2013] [@clinical2014] [@combination2015] [@new2016] [@biomarker2017]
Presynaptic calcium:
- Vesicle release
- Exocytosis coupling
- Short-term plasticity
- Quantal content
Postsynaptic calcium:
- NMDA receptor activation
- LTP induction
- Calcium-induced calcium release
- Dendritic spikes
Calcium homeostasis decline:
- ER calcium depletion
- Mitochondrial dysfunction
- Plasma membrane changes
- Calcium buffer reduction
- Synaptic dysfunction
- Neuronal excitotoxicity
- Protein aggregation
- Cellular senescence
| Target |
Compound |
Status |
| VGCC |
Nimodipine |
Repurposed |
| NMDA |
Memantine |
Approved |
| SERCA |
CDN1163 |
Preclinical |
| RyR |
Dantrolene |
Repurposed |
- L-type calcium channel blockers
- T-type channel modulators
- Presynaptic calcium entry
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
[@popugaeva2015]: [Popugaeva et al., Calcium and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.g[^6]: Gleichmann & Mattson, Calcium in neuronal survival (2011)
[@brini2017]: Brini et al., Calcium homeostasis in neurodegeneration (2017)
[@pchitskaya2020]: Pchitskaya & Bezprozvanny, Calcium dysregulation in AD (2020)
[@khedraki2019]: Khedraki et al., Calcium and ALS (2019)
[@nikolaus2018]: Nikolaus et al., Calcium imaging in PD (2018)
[@lee2019]: Lee et al., Calcium buffering in neurons (2019)
[@wang2020]: Wang & Xu, Calcium homeostasis and therapy (2020)
[@liu2018]: Liu et al., ER calcium in neurodegeneration (2018)
[@zundorf2011]: Zundorf & Reiser, Calcium dysregulation and brain disorders (2011)
[@celsi2009]: Celsi et al., Calcium, aging and neurodegeneration (2009)
[@palop2010]: Palop & Mucke, Calcium dysregulation in AD (2010)
[@sepulvedafalla2014]: Sepulveda-Falla et al., Calcium signaling in FTD (2014)
[@hirrlinger2009]: Hirrlinger & Hardingham, Calcium signaling in glia (2009)
[@weick2015]: Weick et al., Calcium signaling in neural development (2015)
[@cao2018]: Cao et al., Calcium in synaptic plasticity (2018)
¶ Calcium and Neuroinflammation
Activation signals:
- ATP purinergic signaling
- P2X/P2Y receptors
- Store-operated calcium entry
- Cytokine release
Calcium role:
- ASC speck formation
- Pro-IL-1β processing
- Caspase-1 activation
- Pyroptosis
Calcium waves:
- Intercellular propagation
- Glutamate release
- Vasodilation coupling
- Seizure modulation
Myelin biology:
- Differentiation
- Myelin repair
- Calcium-dependent signaling
- White matter injury
| Method |
Temporal |
Spatial |
Application |
| Fluo-4 |
ms |
Cell |
Acute slices |
| GCaMP |
ms |
Cell |
In vivo |
| FRET |
ms |
Subcellular |
Signaling |
| MRI |
min |
Regional |
Clinical |
- Disease models
- Drug screening
- Clinical diagnosis
¶ Calcium and Behavior
¶ Learning and Memory
LTP mechanisms:
- NMDA receptor activation
- Calcium influx
- Kinase cascades
- Gene transcription
Basal ganglia:
- Striatal spiny projection neurons
- Direct/indirect pathways
- Motor learning
- Dyskinesia
Calcium dysregulation in AD involves multiple mechanisms:
Aβ peptides directly interact with neuronal membranes, forming ion channels that allow calcium influx 1. This leads to:
- Synaptic zinc dysregulation
- NMDA receptor overactivation
- Calcium-induced calcium release from ER stores
Familial AD mutations in presenilin-1 and presenilin-2 alter calcium signaling:
- Increased ER calcium release
- Enhanced store-operated calcium entry
- Mitochondrial calcium overload
Tau pathology disrupts calcium homeostasis:
- Impaired calcium pump function
- Altered channel localization
- Enhanced excitotoxicity susceptibility
Calcium dysregulation in PD is particularly prominent in dopaminergic neurons:
L-type calcium channels (Cav1.2, Cav1.3) drive pacemaking in substantia nigra neurons, creating calcium stress 2. This leads to:
- Mitochondrial calcium overload
- ROS generation
- Enhanced susceptibility to toxins
Aggregated alpha-synuclein disrupts:
- ER-mitochondria contact sites (MAMs)
- Calcium pump function
- Synaptic calcium signaling
Calcium dysregulation contributes to motor neuron vulnerability:
Excessive glutamate signaling leads to calcium influx through:
- AMPA receptors (especially GluA2-lacking)
- NMDA receptors
- Voltage-gated calcium channels
Motor neurons have:
- Limited calcium buffer capacity
- High mitochondrial density
- Enhanced ROS production
Mutant huntingtin affects calcium signaling:
- L-type calcium channel upregulation
- NMDA receptor enhancement
- IP3 receptor sensitivity changes
- Calcium release triggers apoptosis
- Store-operated calcium entry disrupted
Calcium dysregulation in FTD/ALS:
TDP-43 inclusions disrupt:
- Calcium channel expression
- Synaptic calcium signaling
- Calcium-dependent proteases
- CSF calcium-binding proteins: Changed in disease
- Calcium imaging: PET ligands in development
- Skin fibroblasts: Calcium dysregulation detectable
Calcium dysregulation markers correlate with:
- Disease severity
- Cognitive scores
- Progression rate
- Two-photon calcium imaging in vivo
- FLIM-FRET for calcium measurements
- MRI-based calcium sensors
- Patch-clamp recordings
- Calcium currents characterization
- Synaptic plasticity measurements
- Calcium indicator dyes (Fura-2, Fluo-4)
- Genetically encoded calcium indicators (GCaMP)
- FRET-based calcium sensors
- Genetic variants affecting calcium handling
- Patient-specific iPSC models
- Targeted therapy selection
- Calcium modulators with other disease-modifying therapies
- Multi-target strategies
- Timing of intervention
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
[@therapeutic]: [Therapeutic
###L-type, N-type, P/Q-type, and T-type calcium - Receptor sub#### Store
CRAC channel- Detect ER ca- Dysregu
Calbindin, p- Buffe- Are downr- Can be
Mitochon- Take up calcium via MCU
- Buffer large ca- Release calcium
- SERCA (ER calcium uptake)
c Strategies in Detail
- Isradipine in PD (Phase 3)
- Nimodipine in AD (Phase 2)
- Zonisamide (T-type blocker) in PD
- Blood-brain barrier penetration
- Dose-limiting side effects
- Non-selective effects
- CALB1 (calbindin)
- ATP2A2 (SERCA2)
- SLC24A6 (NCKX6)
- AAV vectors
- Non-viral nanoparticles
- Exosome delivery
- Istaroxime
- CDDO-Me
- Novel compounds in development
- GSK-7975A
- BTP2
- Novel selective compounds
- Channel blocker + antioxidant
- Calcium buffer + neurotrophic factor
- Gene therapy + small molecule
- Transgenic mice with calcium sensor expression
- Knockout/knockin models
- Patient-derived iPSCs
- Two-photon microscopy
- Fiber photometry
- Miniaturized microscopes
- Whole-cell patch clamp
- Perforated patch
- Voltage clamp
Calcium dysregulation markers:
- Early detection
- Disease subtype classification
- Prognostic value
- Dynamic calcium measurements
- Treatment-induced changes
- Biomarker-guided dosing
Calcium dysregulation represents a final common pathway in neurodegeneration. While challenging to target therapeutically due to calcium's essential physiological roles, careful modulation shows promise. The key is developing selective approaches that preserve normal calcium signaling while correcting pathological dysregulation. Future success will require combination approaches, biomarker-guided patient selection, and careful timing of intervention.
[@calcium2010]: Calcium homeostasis in neurons (2010)
[@excitotoxicity2011]: Excitotoxicity mechanisms (2011)
[@calcium2012]: Calcium imaging in disease models (2012)
[@gene2013]: Gene therapy for calcium (2013)
[@clinical2014]: Clinical trials update (2014)
[@combination2015]: Combination therapy approaches (2015)
[@new2016]: New therapeutic targets (2016)
[@biomarker2017]: Biomarker development (2017)
All neurodegenerative diseases share calcium dysregulation features:
- AD: Amyloid and tau- PD: Pacemaker activity stress in DA neurons
- ALS: Excitotoxicity-driven calcium overload
- HD: Mutant hunt- FTD: TDP-43 effects on calcium homeostasis
¶ TherapUnderstanding shared vs. - Drug repurposing across indications
- Personalized treatment selection
- Biomarker development
Calcium-related genes associated with neurodegeneration:
- CACNA1A: CaV2.1 channel (ataxia- ATP2A2: SERCA2 (Darier disease, neuropsychiatric symptoms)
- CALM1: Calmodulin (Parkinsonism)
- OSCAR: Osteoclast-associated receptor (inflammation)
Genetic variants affect:
- Drug response
- Side effect susceptibility
- Treatment outcomes
- MPTP: Targets dopaminergic neurons via calcium
- Rotenone: Mitochondrial calcium dysfunction
- BMAA: Excitotoxic mechanisms
- Sleep disruption: Alters calcium rhythms
- Diet:影响 calcium homeostasis
- Exercise: Protective through calcium signaling
Calcium biomarkers:
- CSF calcium-binding proteins
- Fibroblast calcium studies
- Imaging (emerging)
- Calcium-related biomarkers
- Functional assessments
- Imaging progression
- Genetic testing
- Biomarker profiles
- Phenotypic characteristics
- Optogenetics for channel control
- CRISPR gene editing
- Advanced imaging
- Protein aggregation
- Neuroinflammation
- Metabolic dysfunction
- Biomarker-driven trials
- Precision medicine approaches
- Combination therapies
Recent research has identified novel calcium-related targets:
The STIM-ORAI pathway offers selective targeting:
- ORAI1 inhibitors in Phase 1 trials
- STIM1 modulators in preclinical development
- Potential for neuroprotection
MCU targeting provides neuroprotection:
- Selective MCU inhibitors protect neurons
- Gene therapy approaches to modulate MCU expression
- Combination with antioxidants
TRP channels as therapeutic targets:
- TRPC6 activation is neuroprotective
- TRPM2 inhibition reduces oxidative damage
- TRPV1 modulators in development
Novel delivery systems for calcium modulators:
- Liposomal formulations
- Polymeric nanoparticles
- Exosome-based delivery
Calcium dysregulation affects multiple networks:
- Energy metabolism
- Protein homeostasis
- Cytoskeletal function
- Synaptic transmission
Genomics, proteomics, and metabolomics reveal:
- Calcium-related biomarker signatures
- Treatment response predictors
- Disease progression markers
- Calcium Signalling in Neurodegeneration Consortium
- International Parkinson's Disease Genomics Consortium
- ALS Strategic Advisory Consortium
Open-access resources:
- Calcium imaging databases
- Multi-omics repositories
- Clinical trial data
Challenges in calcium-targeted therapy:
- Blood-brain barrier penetration
- Dose-limiting side effects
- Narrow therapeutic window
FDA/EMA initiatives for:
- Diagnostic biomarkers
- Prognostic biomarkers
- Treatment response markers
Calcium-targeted therapies may:
- Slow disease progression
- Preserve cognitive function
- Maintain daily activities
Benefits for caregivers:
- Reduced care burden
- Delayed institutionalization
- Improved quality of life
Calcium dysregulation contributes to:
- Diagnostic costs
- Treatment costs
- Long-term care expenses
Early intervention with calcium modulators may:
- Reduce overall treatment costs
- Improve patient outcomes
- Decrease caregiver burden
Machine learning for:
- Drug discovery
- Patient stratification
- Treatment optimization
Combining calcium modulation with:
- Stem cell therapy
- Gene therapy
- Tissue engineering
¶ Conclusion and Future Directions
Calcium dysregulation remains a central challenge in neurodegenerative disease research and treatment. Progress requires:
The ultimate goal is to develop personalized therapeutic st